Clinical Trials: Lowereing A1C, Weight Change & CV Data

See results from clinical trials with Trulicity when assessed for A1C reduction, weight change and CV risk reduction.

Applying Recent A1C Recommendations in Clinical Practice

Clinical dialogue: Lowering ASCVD risk in a patient with T2DM and obesity - PACE-CME

Weight-loss induced by carbohydrate restriction does not negatively affect health-related quality of life and cognition in people with type 2 diabetes: A randomised controlled trial - ScienceDirect

PDF) Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks

Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme - Thethi - 2020 - Diabetes, Obesity and Metabolism - Wiley Online Library

Low-Carb Diet Promising for Lowering Blood Sugar in Prediabetes

Frontiers Changes in body weight and cardiovascular risk factors in a Chinese population with type 2 diabetes mellitus: a longitudinal study

Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin

What the studies say about targets for glycaemic control (including hypoglycaemia)

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023. - Abstract - Europe PMC

RYBELSUS® Results RYBELSUS® (semaglutide) tablets 7 mg or 14 mg

EX-99.1

A quick guide to the SUSTAIN trials